bluebird bio Balance Sheet Health
Financial Health criteria checks 0/6
bluebird bio has a total shareholder equity of $-5.8M and total debt of $80.7M, which brings its debt-to-equity ratio to -1394.4%. Its total assets and total liabilities are $465.1M and $470.8M respectively.
Key information
-1,394.4%
Debt to equity ratio
US$80.68m
Debt
| Interest coverage ratio | n/a |
| Cash | US$70.65m |
| Equity | -US$5.79m |
| Total liabilities | US$470.84m |
| Total assets | US$465.06m |
Recent financial health updates
Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13
Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Recent updates
bluebird bio, Inc.'s (NASDAQ:BLUE) Revenues Are Not Doing Enough For Some Investors
Nov 15bluebird bio: Scientific Success And Financial Success, And The Gap Between
Sep 26bluebird bio's Flight Through Financial Fog And Fierce Rivals
Jun 27bluebird bio Is Priced Below IP Value
Mar 23Bluebird Bio: Innovative Therapies, Monetary Setbacks
Jan 25Is bluebird bio (NASDAQ:BLUE) In A Good Position To Invest In Growth?
Oct 13Here's Why We're A Bit Worried About bluebird bio's (NASDAQ:BLUE) Cash Burn Situation
Jul 13Bluebird, Real Endpoints team up to increase access to pricey gene therapy Zynteglo
Oct 04Bluebird bio names interim finance chief
Sep 26Bluebird bio jumps 17% on FDA approval of new gene therapy
Sep 19bluebird bio' chief strategy and financial officer to depart
Sep 12FDA approves bluebird bio's Zyntego beti-cel gene therapy for beta thalassemia
Aug 17bluebird bio: Potential For 3 Gene Therapy Approvals In 12 Months Makes Buy Case
Jun 22bluebird bio: Beaten Down Biotech With Possible Long-Term Potential
May 09Financial Position Analysis
Short Term Liabilities: BLUE has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: BLUE has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: BLUE has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: BLUE's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BLUE has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BLUE has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.9% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 08:51 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
bluebird bio, Inc. is covered by 34 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Huidong Wang | Barclays |
| Zhiqiang Shu | Berenberg |